ZNRD2-AS1

Across TCGA pan-cancer cohorts, ZNRD2-AS1 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of ZNRD2-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where ZNRD2-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ZNRD2-AS1 is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

LIHC, COAD, and BLCA are the cancer types where ZNRD2-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ZNRD2-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+0.632	<.001	9	view →
COAD	Female	All	+0.573	<.001	9	view →
BLCA	All	All	+0.457	<.001	9	view →
HNSC	All	All	+0.284	.001	7	view →
LUSC	All	All	+0.554	<.001	6	view →
THCA	All	All	−0.291	<.001	6	view →
CHOL	All	All	+0.996	<.001	4	view →
KICH	All	All	−0.549	<.001	4	view →
STAD	All	II,III,IV	+0.380	.006	4	view →
KIRC	Male	II,III,IV	−0.265	.013	4	view →
BRCA	All	III,IV	+0.279	.024	3	view →
PRAD	All	All	+0.364	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

ZNRD2-AS1–LIHC

Open the LIHC breakdown →